Novartis Turns To OTC Co-Packers As Lincoln Plant Lags
This article was originally published in The Tan Sheet
Executive Summary
Originally expected back online by the summer, the Novartis Consumer Health facility in Lincoln, Neb., will not ship any product in 2012. Novartis, which reported consumer sales down 22% to $938 million in Q3, is using third-party manufacturers to restore Excedrin Migraine and other OTCs to market.
You may also be interested in...
GelStat Breaks Into Retail With Migraine Remedy
CEO Larry Gershman says GelStat will launch a marketing campaign to support extending its products for the first time to retail stores. The firm changed its sublingual migraine homeopathic to a single dose from two doses taken five minutes apart.
GelStat Breaks Into Retail With Migraine Remedy
CEO Larry Gershman says GelStat will launch a marketing campaign to support extending its products for the first time to retail stores. The firm changed its sublingual migraine homeopathic to a single dose from two doses taken five minutes apart.
FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls
FDA inspectors were in Novartis Consumer Health’s Lincoln, Neb., plant in December and January, as the company was deciding to halt production and recall products. An inspection report notes 10 observations – eight of them repeats from FDA’s visit in mid-2011.